Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients - a GETUG-AFU Phase III Randomized Controlled Trial

NCT04115007 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT04115007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04115007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients - a GETUG-AFU Phase III Randomized Controlled Trial
Lead sponsor
UNICANCER
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 23, 2020
Completion date
February 28, 2031
Enrollment
550 (estimated)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

oligometastatic hormone sensitive prostate cancer